Nature Communications (Dec 2023)

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

  • Laurence Buisseret,
  • Delphine Loirat,
  • Philippe Aftimos,
  • Christian Maurer,
  • Kevin Punie,
  • Véronique Debien,
  • Paulus Kristanto,
  • Daniel Eiger,
  • Anthony Goncalves,
  • François Ghiringhelli,
  • Donatienne Taylor,
  • Florent Clatot,
  • Tom Van den Mooter,
  • Jean-Marc Ferrero,
  • Hervé Bonnefoi,
  • Jean-Luc Canon,
  • Francois P. Duhoux,
  • Laura Mansi,
  • Renaud Poncin,
  • Philippe Barthélémy,
  • Nicolas Isambert,
  • Zoë Denis,
  • Xavier Catteau,
  • Roberto Salgado,
  • Elisa Agostinetto,
  • Evandro de Azambuja,
  • Françoise Rothé,
  • Ligia Craciun,
  • David Venet,
  • Emanuela Romano,
  • John Stagg,
  • Marianne Paesmans,
  • Denis Larsimont,
  • Christos Sotiriou,
  • Michail Ignatiadis,
  • Martine Piccart-Gebhart

DOI
https://doi.org/10.1038/s41467-023-44071-8
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 1

Abstract

Read online

No abstracts available.